Abstract
The spinocerebellar ataxias (SCAs) comprise more than 40 autosomal dominant neurodegenerative disorders that present principally with progressive ataxia. Within the past few years, studies of pathogenic mechanisms in the SCAs have led to the development of promising therapeutic strategies, especially for SCAs caused by polyglutamine-coding CAG repeats. Nucleotide-based gene-silencing approaches that target the first steps in the pathogenic cascade are one promising approach not only for polyglutamine SCAs but also for the many other SCAs caused by toxic mutant proteins or RNA. For these and other emerging therapeutic strategies, well-coordinated preparation is needed for fruitful clinical trials. To accomplish this goal, investigators from the United States and Europe are now collaborating to share data from their respective SCA cohorts. Increased knowledge of the natural history of SCAs, including of the premanifest and early symptomatic stages of disease, will improve the prospects for success in clinical trials of disease-modifying drugs. In addition, investigators are seeking validated clinical outcome measures that demonstrate responsiveness to changes in SCA populations. Findings suggest that MRI and magnetic resonance spectroscopy biomarkers will provide objective biological readouts of disease activity and progression, but more work is needed to establish disease-specific biomarkers that track target engagement in therapeutic trials. Together, these efforts suggest that the development of successful therapies for one or more SCAs is not far away.
Key points
-
Spinocerebellar ataxias (SCAs) are a group of dominantly inherited degenerative disorders that principally involve the cerebellum and its connections.
-
Insights into the pathogenic mechanisms of many SCAs have suggested promising routes to symptomatic and disease-modifying therapy.
-
Clinical research consortia for SCAs have started international collaborations to share and analyse natural history data.
-
The Scale for Assessment and Rating of Ataxia is the best validated clinical outcome assessment measure, but additional measures should be developed with improved responsiveness to changes that are directly relevant to patients’ lives.
-
MRI and magnetic resonance spectroscopy have emerged as potentially powerful biomarkers for disease activities and progression, but target engagement biomarkers, especially molecular biomarkers in biofluids, are yet to be developed.
-
Collective efforts in SCA clinical research within the past few years have improved the prospects for eventual successful therapeutic development for the SCAs.
Similar content being viewed by others
Change history
08 November 2018
In Table 3 of this article as originally published, a sentence within the column “Comments” in the row “SCA6” contains an error. The text incorrectly reads “Needs rigorous preclinical studies in SCA3 animal models”. This sentence has been corrected to “Needs rigorous preclinical studies in SCA6 animal models” in the PDF and HTML versions of the article.
References
Bird, T. D. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, Seattle, 1998, last updated 2016).
Paulson, H. L., Shakkottai, V. G., Clark, H. B. & Orr, H. T. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat. Rev. Neurosci. 18, 613–626 (2017).
Klockgether, T. The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum 7, 101–105 (2008).
Manto, M. U. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 4, 2–6 (2005).
Giordano, I. et al. Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology 89, 1043–1049 (2017).
van de Warrenburg, B. P. et al. EFNS/ENS consensus on the diagnosis and management of chronic ataxias in adulthood. Eur. J. Neurol. 21, 552–562 (2014).
Menon, R. P. et al. The role of interruptions in polyQ in the pathology of SCA1. PLoS Genet. 9, e1003648 (2013).
Charles, P. et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology 69, 1970–1975 (2007).
Landrian, I. et al. Inheritance patterns of ATCCT repeat interruptions in spinocerebellar ataxia type 10 (SCA10) expansions. PLoS ONE 12, e0175958 (2017).
McFarland, K. N. et al. SMRT sequencing of long tandem nucleotide repeats in SCA10 reveals unique insight of repeat expansion structure. PLoS ONE 10, e0135906 (2015).
Opal, P. & Ashizawa, T. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, Seattle, 1997, last updated 2017).
Socal, M. P. et al. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat. Disord. 15, 374–378 (2009).
Modoni, A. et al. Prevalence of spinocerebellar ataxia type 2 mutation among Italian Parkinsonian patients. Mov. Disord. 22, 324–327 (2007).
Schule, B. et al. Parkinson’s disease associated with pure ATXN10 repeat expansion. NPJ Parkinsons Dis. 3, 27 (2017).
Choubtum, L. et al. Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study. BMC Neurol. 15, 166 (2015).
Wu, Y. R. et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson’s disease. Clin. Genet. 65, 209–214 (2004).
Ross, O. A. et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 20, 3207–3212 (2011).
Elden, A. C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069–1075 (2010).
Yu, Z. et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS ONE 6, e17951 (2011).
McFarland, K. N. et al. Repeat interruptions in spinocerebellar ataxia type 10 expansions are strongly associated with epileptic seizures. Neurogenetics 15, 59–64 (2014).
Nibbeling, E. A. R. et al. Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia. Brain 140, 2860–2878 (2017).
Clarke, J. et al. Continuous base identification for single-molecule nanopore DNA sequencing. Nat. Nanotechnol. 4, 265–270 (2009).
Roberts, R. J., Carneiro, M. O. & Schatz, M. C. The advantages of SMRT sequencing. Genome Biol. 14, 405 (2013).
Ilg, W. et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73, 1823–1830 (2009).
Ilg, W. et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13, 248–268 (2014).
Miyai, I. et al. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil. Neural Repair 26, 515–522 (2012).
Silva, R. C. et al. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz. J. Med. Biol. Res. 43, 537–542 (2010).
Ilg, W. et al. Video game-based coordinative training improves ataxia in children with degenerative ataxia. Neurology 79, 2056–2060 (2012).
Fonteyn, E. M. et al. Gait adaptability training improves obstacle avoidance and dynamic stability in patients with cerebellar degeneration. Gait Posture 40, 247–251 (2014).
Chang, Y. J. et al. Cycling regimen induces spinal circuitry plasticity and improves leg muscle coordination in individuals with spinocerebellar ataxia. Arch. Phys. Med. Rehabil. 96, 1006–1013 (2015).
Fonteyn, E. M. et al. The effectiveness of allied health care in patients with ataxia: a systematic review. J. Neurol. 261, 251–258 (2014).
Ihara, Y., Takata, H., Tanabe, Y., Nobukuni, K. & Hayabara, T. Influence of repetitive transcranial magnetic stimulation on disease severity and oxidative stress markers in the cerebrospinal fluid of patients with spinocerebellar degeneration. Neurol. Res. 27, 310–313 (2005).
Shiga, Y. et al. Transcranial magnetic stimulation alleviates truncal ataxia in spinocerebellar degeneration. J. Neurol. Neurosurg. Psychiatry 72, 124–126 (2002).
Zu, T. et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853–8861 (2004).
Furrer, S. A. et al. Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7. Hum. Mol. Genet. 22, 890–903 (2013).
Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101, 57–66 (2000).
Katsuno, M. et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci. 26, 12106–12117 (2006).
Sanchez, I., Balague, E. & Matilla-Duenas, A. Ataxin-1 regulates the cerebellar bioenergetics proteome through the GSK3beta-mTOR pathway which is altered in Spinocerebellar ataxia type 1 (SCA1). Hum. Mol. Genet. 25, 4021–4040 (2016).
Lim, J. et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 125, 801–814 (2006).
Crespo-Barreto, J., Fryer, J. D., Shaw, C. A., Orr, H. T. & Zoghbi, H. Y. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet. 6, e1001021 (2010).
Matilla-Duenas, A., Goold, R. & Giunti, P. Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 7, 106–114 (2008).
Busch, A. et al. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington’s disease. J. Biol. Chem. 278, 41452–41461 (2003).
Cattaneo, E. et al. Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 24, 182–188 (2001).
Evers, M. M., Toonen, L. J. & van Roon-Mom, W. M. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol. Neurobiol. 49, 1513–1531 (2014).
Tsoi, H. & Chan, H. Y. Expression of expanded CAG transcripts triggers nucleolar stress in Huntington’s disease. Cerebellum 12, 310–312 (2013).
Samaraweera, S. E. et al. Modeling and analysis of repeat RNA toxicity in Drosophila. Methods Mol. Biol. 1017, 173–192 (2013).
Shieh, S. Y. & Bonini, N. M. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila. Hum. Mol. Genet. 20, 4810–4821 (2011).
Li, L. B., Yu, Z., Teng, X. & Bonini, N. M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 453, 1107–1111 (2008).
Moseley, M. L. et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38, 758–769 (2006).
Ikeda, Y., Daughters, R. S. & Ranum, L. P. Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes. Cerebellum 7, 150–158 (2008).
Li, P. P. et al. ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. Ann. Neurol. 80, 600–615 (2016).
Sopher, B. L. et al. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 70, 1071–1084 (2011).
Zu, T. et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA 108, 260–265 (2011).
Ishiguro, T. et al. Regulatory role of RNA chaperone TDP-43 for RNA misfolding and repeat-associated translation in sCA31. Neuron 94, 108–124 e7 (2017).
Sellier, C. et al. Translation of expanded CGG repeats into FMRpolyG is pathogenic and may contribute to fragile X tremor ataxia syndrome. Neuron 93, 331–347 (2017).
Krans, A., Kearse, M. G. & Todd, P. K. Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome. Ann. Neurol. 80, 871–881 (2016).
Scoles, D. R. et al. Repeat associated non-AUG translation (RAN translation) dependent on sequence downstream of the ATXN2 CAG repeat. PLoS ONE 10, e0128769 (2015).
Ashizawa, T. & Wells, R. D. Genetic Instabilities and Neurological Disorders (Elsevier, Burlington, 2006).
Stella, S., Alcon, P. & Montoya, G. Class 2 CRISPR-Cas RNA-guided endonucleases: Swiss Army knives of genome editing. Nat. Struct. Mol. Biol. 24, 882–892 (2017).
Murugan, K., Babu, K., Sundaresan, R., Rajan, R. & Sashital, D. G. The revolution continues: newly discovered systems expand the CRISPR-Cas toolkit. Mol. Cell 68, 15–25 (2017).
Monteys, A. M., Ebanks, S. A., Keiser, M. S. & Davidson, B. L. CRISPR/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo. Mol. Ther. 25, 12–23 (2017).
Cornu, T. I., Mussolino, C. & Cathomen, T. Refining strategies to translate genome editing to the clinic. Nat. Med. 23, 415–423 (2017).
Maxwell, K. L. The anti-CRISPR story: a battle for survival. Mol. Cell 68, 8–14 (2017).
Fiszer, A. & Krzyzosiak, W. J. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 42, 6787–6810 (2014).
Keiser, M. S., Kordasiewicz, H. B. & McBride, J. L. Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington’s disease and spinocerebellar ataxia. Hum. Mol. Genet. 25, R53–R64 (2016).
Miyazaki, Y., Du, X., Muramatsu, S. & Gomez, C. M. An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron. Sci. Transl Med. 8, 347ra94 (2016).
Tabrizi, S. et al. Effects of IONIS-HTTRx in patients with early Huntington’s disease, results of the first HTT-lowering drug trial. Neurology 90 (Suppl. 15), CT.002 (2018).
Zoghbi, H. Y. & Orr, H. T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 284, 7425–7429 (2009).
Park, J. et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 498, 325–331 (2013).
Teixeira-Castro, A. et al. Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 138, 3221–3237 (2015).
Costa, M. D. et al. Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain 139, 2891–2908 (2016).
Reis, S. D., Pinho, B. R. & Oliveira, J. M. A. Modulation of molecular chaperones in Huntington’s disease and other polyglutamine disorders. Mol. Neurobiol. 54, 5829–5854 (2017).
Ding, Y. et al. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1. Neuroscience 327, 20–31 (2016).
Cushman-Nick, M., Bonini, N. M. & Shorter, J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. PLoS Genet. 9, e1003781 (2013).
Nagai, Y., Fujikake, N., Popiel, H. A. & Wada, K. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr. Pharm. Biotechnol. 11, 188–197 (2011).
Tsou, W. L. et al. DnaJ-1 and karyopherin a3 suppress degeneration in a new Drosophila model of spinocerebellar ataxia Type 6. Hum. Mol. Genet. 24, 4385–4396 (2015).
Williams, A. J., Knutson, T. M., Colomer Gould, V. F. & Paulson, H. L. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol. Dis. 33, 342–353 (2009).
Alves, S. et al. The autophagy/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice. Acta Neuropathol. 128, 705–722 (2014).
Ashkenazi, A. et al. Polyglutamine tracts regulate beclin 1-dependent autophagy. Nature 545, 108–111 (2017).
Onofre, I. et al. Fibroblasts of Machado Joseph disease patients reveal autophagy impairment. Sci. Rep. 6, 28220 (2016).
Baron, O. et al. Stall in canonical autophagy-lysosome pathways prompts nucleophagy-based nuclear breakdown in neurodegeneration. Curr. Biol. 27, 3626–3642 (2017).
Coutelier, M. et al. A panel study on patients with dominant cerebellar ataxia highlights the frequency of channelopathies. Brain 140, 1579–1594 (2017).
Jen, J. C., Ashizawa, T., Griggs, R. C. & Waters, M. F. Rare neurological channelopathies — networks to study patients, pathogenesis and treatment. Nat. Rev. Neurol. 12, 195–203 (2016).
Bever, C. T. Jr et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054–1059 (1994).
Goodman, A. D. et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373, 732–738 (2009).
Hourez, R. et al. Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 31, 11795–11807 (2011).
Jayabal, S., Chang, H. H., Cullen, K. E. & Watt, A. J. 4-Aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6. Sci. Rep. 6, 29489 (2016).
Sobue, I. et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J. Neurol. Sci. 61, 235–248 (1983).
Kanazawa, I. et al. Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration: a multi-center double-blind comparative study with placebo. J. Clin. Ther. Med. 13, 4169–4224 (1997).
Ranganathan, R. NINDS translational programs: priming the pump of neurotherapeutics discovery and development. Neuron 84, 515–520 (2014).
Bushart, D. D. & Shakkottai, V. G. Ion channel dysfunction in cerebellar ataxia. Neurosci. Lett. https://doi.org/10.1016/j.neulet.2018.02.005 (2018).
Kasumu, A. W. et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem. Biol. 19, 1340–1353 (2012).
Gao, Z. et al. Cerebellar ataxia by enhanced Ca(V)2.1 currents is alleviated by Ca2+-dependent K+-channel activators in Cacna1a(S218L) mutant mice. J. Neurosci. 32, 15533–15546 (2012).
Grasselli, G. et al. Activity-dependent plasticity of spike pauses in cerebellar Purkinje cells. Cell Rep. 14, 2546–2553 (2016).
Hosy, E., Piochon, C., Teuling, E., Rinaldo, L. & Hansel, C. SK2 channel expression and function in cerebellar Purkinje cells. J. Physiol. 589, 3433–3440 (2011).
Shakkottai, V. G. et al. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J. Clin. Invest. 113, 582–590 (2004).
Ohtsuki, G., Piochon, C., Adelman, J. P. & Hansel, C. SK2 channel modulation contributes to compartment-specific dendritic plasticity in cerebellar Purkinje cells. Neuron 75, 108–120 (2012).
Dell’Orco, J. M., Pulst, S. M. & Shakkottai, V. G. Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2. Hum. Mol. Genet. 26, 3935–3945 (2017).
Bushart, D. D. et al. Targeting potassium channels to treat cerebellar ataxia. Ann. Clin. Transl Neurol. 5, 297–314 (2018).
Egorova, P. A., Zakharova, O. A., Vlasova, O. L. & Bezprozvanny, I. B. In vivo analysis of cerebellar Purkinje cell activity in SCA2 transgenic mouse model. J. Neurophysiol. 115, 2840–2851 (2016).
Ristori, G. et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74, 839–845 (2010).
Romano, S. et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985–991 (2015).
Leone, M., Bottacchi, E., D’Alessandro, G. & Kustermann, S. Hereditary ataxias and paraplegias in Valle d’Aosta, Italy: a study of prevalence and disability. Acta Neurol. Scand. 91, 183–187 (1995).
Silva, M. C., Coutinho, P., Pinheiro, C. D., Neves, J. M. & Serrano, P. Hereditary ataxias and spastic paraplegias: methodological aspects of a prevalence study in Portugal. J. Clin. Epidemiol. 50, 1377–1384 (1997).
van de Warrenburg, B. P. et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 58, 702–708 (2002).
Ruano, L., Melo, C., Silva, M. C. & Coutinho, P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 42, 174–183 (2014).
NIH. Rare diseases clinical research network. nih.gov https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=126 (2018).
Schmitz-Hübsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717–1720 (2006).
Ashizawa, T. et al. Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J. Rare Dis. 8, 177 (2013).
Jacobi, H. et al. Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 14, 1101–1108 (2015).
Jacobi, H. et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol. 12, 650–658 (2013).
Jacobi, H. et al. Spinocerebellar ataxia types 1, 2, 3 and 6: the clinical spectrum of ataxia and morphometric brainstem and cerebellar findings. Cerebellum 11, 155–166 (2012).
Saute, J. A. et al. Planning future clinical trials in Machado Joseph disease: lessons from a phase 2 trial. J. Neurol. Sci. 358, 72–76 (2015).
Maas, R. P., van Gaalen, J., Klockgether, T. & van de Warrenburg, B. P. The preclinical stage of spinocerebellar ataxias. Neurology 85, 96–103 (2015).
Rubinsztein, D. C. & Orr, H. T. Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: there may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile. Bioessays 38, 977–980 (2016).
Trouillas, P. et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J. Neurol. Sci. 145, 205–211 (1997).
Schmahmann, J. D., Macmore, J. & Vangel, M. Cerebellar stroke without motor deficit: clinical evidence for motor and non-motor domains within the human cerebellum. Neuroscience 162, 852–861 (2009).
Schmahmann, J. D., Gardner, R., MacMore, J. & Vangel, M. G. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov. Disord. 24, 1820–1828 (2009).
Kieling, C. et al. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur. J. Neurol. 15, 371–376 (2008).
Saute, J. A. et al. Ataxia rating scales—psychometric profiles, natural history and their application in clinical trials. Cerebellum 11, 488–504 (2012).
Monte, T. L. et al. NESSCA validation and responsiveness of several rating scales in spinocerebellar ataxia type 2. Cerebellum 16, 852–858 (2017).
du Montcel, S. T. et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 131, 1352–1361 (2008).
Schmitz-Hubsch, T. et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71, 486–492 (2008).
Chini, G. et al. Local stability of the trunk in patients with degenerative cerebellar ataxia during walking. Cerebellum 16, 26–33 (2017).
Schmitz-Hübsch, T. et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 74, 678–684 (2010).
Chan, E. et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov. Disord. 26, 534–538 (2011).
Hickey, A. et al. Validity of a wearable accelerometer to quantify gait in spinocerebellar ataxia type 6. Physiol. Meas. 37, N105–N117 (2016).
Subramony, S. H. et al. Objective home-based gait assessment in spinocerebellar ataxia. J. Neurol. Sci. 313, 95–98 (2012).
Tezenas du Montcel, S. et al. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain 137, 2444–2455 (2014).
Chen, Z. et al. (CAG)n loci as genetic modifiers of age-at-onset in patients with Machado-Joseph disease from mainland China. Brain 139, e41 (2016).
Long, Z. et al. Two novel SNPs in ATXN3 3′UTR may decrease age at onset of SCA3/MJD in Chinese patients. PLoS ONE 10, e0117488 (2015).
Peng, H. et al. APOE epsilon2 allele may decrease the age at onset in patients with spinocerebellar ataxia type 3 or Machado-Joseph disease from the Chinese Han population. Neurobiol. Aging 35, 2179e15–2179e18 (2014).
Wang, C. et al. Analysis of the GGGGCC repeat expansions of the C9orf72 gene in SCA3/MJD patients from China. PLoS ONE 10, e0130336 (2015).
Raposo, M. et al. Promoter variation and expression levels of inflammatory genes IL1A, IL1B, IL6 and TNF in blood of spinocerebellar ataxia type 3 (SCA3) patients. Neuromol. Med. 19, 41–45 (2017).
Tezenas du Montcel, S. et al. Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia. Arch. Neurol. 69, 500–508 (2012).
Zhou, Q. et al. The role of apolipoprotein E as a risk factor for an earlier age at onset for Machado-Joseph disease is doubtful. PLoS ONE 9, e111356 (2014).
de Castilhos, R. M. et al. Spinocerebellar ataxias in Brazil—frequencies and modulating effects of related genes. Cerebellum 13, 17–28 (2014).
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89–95 (2001).
Mueller, S. G., Schuff, N. & Weiner, M. W. Evaluation of treatment effects in Alzheimer’s and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 19, 655–668 (2006).
Reetz, K. et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain 136, 905–91711 (2013).
Currie, S. et al. Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction. Cerebellum 12, 245–266 (2013).
Kang, N. et al. Sensory and motor cortex function contributes to symptom severity in spinocerebellar ataxia type 6. Brain Struct. Funct. 222, 1039–1052 (2017).
Duarte, J. V. et al. Parametric fMRI of paced motor responses uncovers novel whole-brain imaging biomarkers in spinocerebellar ataxia type 3. Hum. Brain Mapp. 37, 3656–3668 (2016).
Klockgether, T. et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 121, 1687–1693 (1998).
Schulz, J. B. et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 49, 158–168 (2010).
Della Nave, R. et al. Brain white matter damage in SCA1 and SCA2. An in vivo study using voxel-based morphometry, histogram analysis of mean diffusivity and tract-based spatial statistics. Neuroimage 43, 10–19 (2008).
Mandelli, M. L. et al. Diffusion tensor imaging of spinocerebellar ataxias types 1 and 2. Am. J. Neuroradiol. 28, 1996–2000 (2007).
Prakash, N. et al. Patterns of fractional anisotropy changes in white matter of cerebellar peduncles distinguish spinocerebellar ataxia-1 from multiple system atrophy and other ataxia syndromes. Neuroimage 47 (Suppl. 2), T72–T81 (2009).
Guimaraes, R. P. et al. A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3. Mov. Disord. 28, 1125–1132 (2013).
Solodkin, A., Peri, E., Chen, E. E., Ben-Jacob, E. & Gomez, C. M. Loss of intrinsic organization of cerebellar networks in spinocerebellar ataxia type 1: correlates with disease severity and duration. Cerebellum 10, 218–232 (2011).
Falcon, M. I., Gomez, C. M., Chen, E. E., Shereen, A. & Solodkin, A. Early cerebellar network shifting in spinocerebellar ataxia type 6. Cereb. Cortex 26, 3205–3218 (2016).
Mascalchi, M. et al. Progression of microstructural damage in spinocerebellar ataxia type 2: a longitudinal DTI study. Am. J. Neuroradiol 36, 1096–1101 (2015).
Dayan, M. et al. Impact of cerebellar atrophy on cortical gray matter and cerebellar peduncles as assessed by voxel-based morphometry and high angular resolution diffusion imaging. Funct. Neurol. 31, 239–248 (2016).
Rozenfeld, M. N. et al. An investigation of diffusion imaging techniques in the evaluation of spinocerebellar ataxia and multisystem atrophy. J. Clin. Neurosci. 22, 166–172 (2015).
Öz, G. et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 270, 658–679 (2014).
Viau, M. & Boulanger, Y. Characterization of ataxias with magnetic resonance imaging and spectroscopy. Parkinsonism Relat. Disord. 10, 335–351 (2004).
Öz, G. in Handbook of the Cerebellum and Cerebellar Disorders (eds Manto, M., Gruol, D. L., Schmahman, J. D., Koibuchi, N. & Rossi, F.) (Springer, Dordrecht, 2013).
Joers, J. M. et al. Neurochemical abnormalities in premanifest and early spinocerebellar ataxias. Ann. Neurol. 83, 816–829 (2018).
Öz, G. et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov. Disord. 25, 1253–1261 (2010).
Öz, G. et al. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 10, 208–217 (2011).
Adanyeguh, I. M. et al. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov. Disord. 30, 662–670 (2015).
Deelchand, D. K. et al. High field MRS is more sensitive to progression of neurodegeneration than clinical decline in spinocerebellar ataxia type 1 (SCA1). Proc. Int. Soc. Magn. Reson. Med. 22, 64 (2014).
Öz, G. et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 30, 3831–3838 (2010).
Öz, G. et al. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp. Neurol. 232, 290–298 (2011).
Öz, G. et al. Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology. Neurobiol. Dis. 74, 158–166 (2015).
Emir, U. E., Brent Clark, H., Vollmers, M. L., Eberly, L. E. & Öz, G. Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J. Neurochem. 127, 660–668 (2013).
Terpstra, M. et al. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T. Magn. Reson. Med. 76, 1083–1091 (2016).
Deelchand, D. K. et al. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. Magn. Reson. Med. 73, 1718–1725 (2015).
van de Bank, B. L. et al. Multi-center reproducibility of neurochemical profiles in the human brain at 7 T. NMR Biomed. 28, 306–316 (2015).
Mascalchi, M. et al. Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. Ann. Neurol. 43, 244–252 (1998).
Ragno, M. et al. Multimodal electrophysiologic follow-up study in 3 mutated but presymptomatic members of a spinocerebellar ataxia type 1 (SCA1) family. Neurol. Sci. 26, 67–71 (2005).
Yoo, Y. J. & Oh, J. Identification of early neurodegenerative change in presymptomatic spinocerebellar ataxia type 1: a diffusion tensor imaging study. Parkinsonism Relat. Disord. 36, 109–110 (2017).
D’Abreu, A. et al. Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study. J. Neuroimag. 22, 285–291 (2012).
Brouillette, A. M., Öz, G. & Gomez, C. M. Cerebrospinal fluid biomarkers in spinocerebellar ataxia: a pilot study. Dis. Markers 2015, 413098 (2015).
de Assis, A. M. et al. Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3/Machado-Joseph disease. Front. Neurol. 8, 485 (2017).
da Silva Carvalho, G. et al. Cytokines in Machado Joseph disease/spinocerebellar ataxia 3. Cerebellum 15, 518–525 (2016).
Almaguer-Gotay, D. et al. Role of glutathione S-transferases in the spinocerebellar ataxia type 2 clinical phenotype. J. Neurol. Sci. 341, 41–45 (2014).
Swarup, V., Srivastava, A. K., Padma, M. V. & Rajeswari, M. R. Quantification of circulating plasma DNA in Friedreich’s ataxia and spinocerebellar ataxia types 2 and 12. DNA Cell Biol. 30, 389–394 (2011).
Cuello-Almarales, D. A. et al. Buccal cell micronucleus frequency is significantly elevated in patients with spinocerebellar ataxia type 2. Arch. Med. Res. 48, 297–302 (2017).
Pula, J. H. et al. Retinal nerve fibre layer and macular thinning in spinocerebellar ataxia and cerebellar multisystem atrophy. Neuroophthalmology 35, 108–114 (2011).
Alvarez, G. et al. Optical coherence tomography findings in spinocerebellar ataxia-3. Eye 27, 1376–1381 (2013).
Panouilleres, M. T. N. et al. Sensorimotor adaptation as a behavioural biomarker of early spinocerebellar ataxia type 6. Sci. Rep. 7, 2366 (2017).
Seifried, C. et al. Saccade velocity as a surrogate disease marker in spinocerebellar ataxia type 2. Ann. NY Acad. Sci. 1039, 524–527 (2005).
Wu, C. et al. Oculomotor deficits in spinocerebellar ataxia type 3: potential biomarkers of preclinical detection and disease progression. CNS Neurosci. Ther. 23, 321–328 (2017).
Rodriguez-Labrada, R. et al. Saccadic latency is prolonged in spinocerebellar ataxia type 2 and correlates with the frontal-executive dysfunctions. J. Neurol. Sci. 306, 103–107 (2011).
Rodriguez-Labrada, R. et al. Executive deficit in spinocerebellar ataxia type 2 is related to expanded CAG repeats: evidence from antisaccadic eye movements. Brain Cogn. 91, 28–34 (2014).
Rodriguez-Labrada, R. et al. Spinocerebellar ataxia type 2: measures of saccade changes improve power for clinical trials. Mov. Disord. 31, 570–578 (2016).
Colen, C. B., Ketko, A., George, E. & Van Stavern, G. P. Periodic alternating nystagmus and periodic alternating skew deviation in spinocerebellar ataxia type 6. J. Neuroophthalmol. 28, 287–288 (2008).
Rodriguez-Labrada, R. et al. Subtle rapid eye movement sleep abnormalities in presymptomatic spinocerebellar ataxia type 2 gene carriers. Mov. Disord. 26, 347–350 (2011).
Velazquez-Perez, L. et al. Sleep disorders in spinocerebellar ataxia type 2 patients. Neurodegener. Dis. 8, 447–454 (2011).
Dang, D. & Cunnington, D. Excessive daytime somnolence in spinocerebellar ataxia type 1. J. Neurol. Sci. 290, 146–147 (2010).
Velazquez-Perez, L. et al. Progression markers of Spinocerebellar ataxia 2. A twenty years neurophysiological follow up study. J. Neurol. Sci. 290, 22–26 (2010).
Velazquez-Perez, L. et al. Motor decline in clinically presymptomatic spinocerebellar ataxia type 2 gene carriers. PLoS ONE 4, e5398 (2009).
Ilg, W. et al. Individual changes in preclinical spinocerebellar ataxia identified via increased motor complexity. Mov Disord. 31, 1891–1900 (2016).
Dominguez, C. Imaging mutant huntingtin aggregates: development of potential PET ligands. Oral Presentation, 253rd ACS National Meeting & Exposition, San Francisco, CA, United States, 2–6 April 2017, MEDI-320 (2017).
Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816–820 (2004).
Keiser, M. S., Boudreau, R. L. & Davidson, B. L. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol. Ther. 22, 588–595 (2014).
Keiser, M. S., Monteys, A. M., Corbau, R., Gonzalez-Alegre, P. & Davidson, B. L. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Ann. Neurol. 80, 754–765 (2016).
National Institute of Neurological Disorders and Stroke. CREATE-Bio program overview. NINDS https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Translational-Research/CREATE-BIO (2014).
National Institute of Neurological Disorders and Stroke. CREATE-Bio examples: milestones. NINDS https://www.ninds.nih.gov/Funding/Apply-Funding/Application-Support-Library/CREATE-Bio-Examples-Milestones (2014).
Liu, J. et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J. Neurosci. 29, 9148–9162 (2009).
Chen, X. et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 28, 12713–12724 (2008).
Alves, S. et al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS ONE 3, e3341 (2008).
Alves, S. et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum. Mol. Genet. 19, 2380–2394 (2010).
Nóbrega, C. et al. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease. PLoS ONE 9, e100086 (2014).
Rodriguez-Lebron, E. et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol. Ther. 21, 1909–1918 (2013).
Costa Mdo, C. et al. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol. Ther. 21, 1898–1908 (2013).
Scoles, D. R. et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544, 362–366 (2017).
Moore, L. R. et al. Evaluation of antisense oligonucleotides targeting ATXN3 in SCA3 mouse models. Mol. Ther. Nucleic Acids 7, 200–210 (2017).
Toonen, L. J. A., Rigo, F., van Attikum, H. & van Roon-Mom, W. M. C. Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol. Ther. Nucleic Acids 8, 232–242 (2017).
Ramachandran, P. S. et al. RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration. PLOS One 9, e95362 (2014).
Ramachandran, P. S., Boudreau, R. L., Schaefer, K. A., La Spada, A. R. & Davidson, B. L. Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Mol. Ther. 22, 1635–1642 (2014).
Strupp, M. et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77, 269–275 (2011).
Giordano, I. et al. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J. Neurol. 260, 2175–2176 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01811706 (2015)
Power, E. M., Morales, A. & Empson, R. M. Prolonged type 1 metabotropic glutamate receptor dependent synaptic signaling contributes to spino-cerebellar ataxia type 1. J. Neurosci. 36, 4910–4916 (2016).
Notartomaso, S. et al. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol. Brain 6, 48 (2013).
Watson, L. M. et al. Dominant mutations in GRM1 cause spinocerebellar ataxia type 44. Am. J. Hum. Genet. 101, 451–458 (2017).
Acknowledgements
This work was supported by a grant from the US NIH (U01 NS104326-01) to T.A. (contact principal investigator), G.Ö. (multiple principal investigator) and H.L.P. (multiple principal investigator). T.A. is funded by the NIH (R01 NS083564), the National Ataxia Foundation and the Harriet and Joe B. Foster Endowment Fund on spinocerebellar ataxia (SCA) research and is collaborating with Pacific Biosciences on single-molecule real-time sequencing of the expanded SCA10 tandem repeat. G.Ö. receives grant funding from the NIH (R01 NS080816), the National Ataxia Foundation and Takeda Pharmaceuticals on SCA research. The Center for Magnetic Resonance Research is supported by the US National Institute of Biomedical Imaging and Bioengineering grant P41 EB015894 and the US Institutional Center Cores for Advanced Neuroimaging award P30 NS076408. H.L.P.’s work on SCAs is funded by the NIH (R01 NS038712), the National Ataxia Foundation, the Alfred Taubman Medical Research Institute, the University of Michigan Center for the Discovery of New Medicines, Cydan and the SCA Network of Sweden. He collaborates with Ionis Pharmaceuticals on antisense oligonucleotide therapy development for SCA3. The authors thank C. Potvin for helping with manuscript preparation and L. Eberly for assistance with sample size calculations.
Author information
Authors and Affiliations
Contributions
All authors researched data for the article, made substantial contributions to discussion of content, wrote the article and reviewed and/or edited the article before submission.
Corresponding author
Ethics declarations
Competing interests
T.A. has received honoraria and travel support from Pacific Biosciences. G.Ö. has received funding from Takeda Pharmaceuticals for a spinocerebellar ataxia (SCA) preclinical trial. H.L.P. recently completed a research contract with Ionis Pharmaceuticals for ASO treatments of SCA3.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Ashizawa, T., Öz, G. & Paulson, H.L. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol 14, 590–605 (2018). https://doi.org/10.1038/s41582-018-0051-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-018-0051-6
- Springer Nature Limited
This article is cited by
-
Hexanucleotide repeat expansion in SCA36 reduces the expression of genes involved in ribosome biosynthesis and protein translation
Journal of Human Genetics (2024)
-
A Cysteinyl-tRNA Synthetase Mutation Causes Novel Autosomal-Dominant Inheritance of a Parkinsonism/Spinocerebellar-Ataxia Complex
Neuroscience Bulletin (2024)
-
Psychometric Validation of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) in Patients With Spinocerebellar Ataxia
The Cerebellum (2024)
-
Identification and characterisation of pathogenic and non-pathogenic FGF14 repeat expansions
Nature Communications (2024)
-
Reactive Bergmann glia play a central role in spinocerebellar ataxia inflammation via the JNK pathway
Journal of Neuroinflammation (2023)